Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Laura Layos"'
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11403 (2023)
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as p
Externí odkaz:
https://doaj.org/article/c4273883658f4a7083f3fb2081e5498d
Autor:
Gabriela Antelo, Cinta Hierro, Juan Pablo Fernández, Eduardo Baena, Cristina Bugés, Laura Layos, José Luis Manzano, Mónica Caro, Ricard Mesia
Publikováno v:
Drugs in Context, Vol 9, Pp 1-13 (2020)
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumours, which can be classified into neuroendocrine tumours (NETs), neuroendocrine carcinomas (NECs) and mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs). To date, there is
Externí odkaz:
https://doaj.org/article/5dde89858f5c4490bf582d81d485bda4
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 22, p 14058 (2022)
Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women. Treatment of metastatic CRC consists of highly toxic chemotherapeutic drug combinations that often negatively affect patient quality of life (QoL). Mo
Externí odkaz:
https://doaj.org/article/f239edf0605a4bd097c3384533652797
Autor:
Alba Ginés, Sara Bystrup, Vicenç Ruiz de Porras, Cristina Guardia, Eva Musulén, Anna Martínez-Cardús, José Luis Manzano, Laura Layos, Albert Abad, Eva Martínez-Balibrea
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0123830 (2015)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplati
Externí odkaz:
https://doaj.org/article/db9b14ae152947aa823c7a183722175b
Publikováno v:
Clinical Colorectal Cancer. 21:71-79
In recent years, studies on the molecular typing of colorectal cancer have matured, and the V-raf murine sarcoma viral oncogene homolog B (BRAF) of the mitogen-activated protein kinase pathway has been shown to be an important effector molecule of th
Publikováno v:
Seminars in Cancer Biology. 73:321-330
Colorectal cancer (CRC) is the second cause of cancer death worldwide. The metastatic disease is mainly treated with aggressive therapies consisting on combinations of cytotoxic chemotherapy plus anti-EGFR or anti-VEGF drugs. In spite of the improvem
Autor:
Monica Caro, Cinta Hierro, Ricard Mesia, Jose Luis Manzano, Cristina Buges, Laura Layos, Gabriela Antelo, Eduardo Baena, Juan Pablo Fernández
Publikováno v:
Drugs in Context
Drugs in Context, Vol 9, Pp 1-13 (2020)
Drugs in Context, Vol 9, Pp 1-13 (2020)
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumours, which can be classified into neuroendocrine tumours (NETs), neuroendocrine carcinomas (NECs) and mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs). To date, there is
Autor:
Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, Javier Gallego, Paula Jiménez-Fonseca, Fernando Rivera, Maria Teresa Cano, Mercedes Rodríguez Garrote, Carles Pericay, Inmaculada Diaz, Laura Layos, Begoña Graña, Vega Iranzo, Inmaculada Gallego-Jimenez, Rocio Garcia-Carbonero, Maria Alvarez Alejandro, Inmaculada Ruiz de Mena, CARMEN GUILLEN PONCE, Enrique Aranda
Publikováno v:
Journal of Clinical Oncology. 40:4022-4022
4022 Background: Sequential treatment with nab-paclitaxel, gemcitabine followed by oxaliplatin, leucovorin and 5-fluorouracil ( nab-P/Gem-mFOLFOX) have shown a good safety profile and clinical activity in metastatic pancreatic ductal adenocarcinoma (
Autor:
Eudald Felip, Lucia Gutierrez-Chamorro, Maica Gómez, Edurne Garcia-Vidal, Margarita Romeo, Teresa Moran Bueno, Laura Layos, Laia Perez-Roca, Eva Riveira-Muñoz, Bonaventura Clotet, Pedro Luis Fernanadez, Ricard Mesia, Anna Martinez-Cardús, Ester Ballana, Mireia Margeli Vila
Publikováno v:
SSRN Electronic Journal.
Autor:
Eric, Van Cutsem, Margaret A, Tempero, Darren, Sigal, Do-Youn, Oh, Nicola, Fazio, Teresa, Macarulla, Erika, Hitre, Pascal, Hammel, Andrew E, Hendifar, Susan E, Bates, Chung-Pin, Li, Sunil R, Hingorani, Christelle, de la Fouchardiere, Anup, Kasi, Volker, Heinemann, Anthony, Maraveyas, Nathan, Bahary, Laura, Layos, Vaibhav, Sahai, Lei, Zheng, Jill, Lacy, Joon Oh, Park, Fabienne, Portales, Paul, Oberstein, Wilson, Wu, Dimitrios, Chondros, Andrea J, Bullock
Publikováno v:
Scientia
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8b97ebf9ba99cec6f3515308b207bd
https://hdl.handle.net/11351/6453
https://hdl.handle.net/11351/6453